{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T05:27:23Z","timestamp":1775453243151,"version":"3.50.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Asia-Pacific Journal of Ophthalmology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.apjo.2026.100298","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T17:06:59Z","timestamp":1772557619000},"page":"100298","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Factors predicting fluid-free retina and complete polypoidal regression in polypoidal choroidal vasculopathy eyes receiving 2-mg aflibercept treatments"],"prefix":"10.1016","volume":"15","author":[{"given":"Voraporn","family":"Chaikitmongkol","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thidarat","family":"Somkuna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0124-722X","authenticated-orcid":false,"given":"Direk","family":"Patikulsila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paisan","family":"Ruamviboonsuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pichai","family":"Jirarattanasopa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Titipol","family":"Srisomboon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chanusnun","family":"Narongchai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5152-3918","authenticated-orcid":false,"given":"Mansing","family":"Ratanasukon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patama","family":"Bhurayanontachai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4997-6285","authenticated-orcid":false,"given":"Paradee","family":"Kunavisarut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nawat","family":"Watanachai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5972-0270","authenticated-orcid":false,"given":"Janejit","family":"Choovuthayakorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peranut","family":"Chotcomwongse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Apisara","family":"Sangkaew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thammasin","family":"Ingviya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil M.","family":"Bressler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.apjo.2026.100298_bib1","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.preteyeres.2016.04.002","article-title":"Age-related macular degeneration and polypoidal choroidal vasculopathy in Asians","volume":"53","author":"Wong","year":"2016","journal-title":"Prog Retin Eye Res"},{"issue":"4","key":"10.1016\/j.apjo.2026.100298_bib2","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/s41433-023-02764-w","article-title":"Macular neovascularization and polypoidal choroidal vasculopathy: phenotypic variations, pathogenic mechanisms and implications in management","volume":"38","author":"Cheung","year":"2024","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.apjo.2026.100298_bib3","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ajo.2022.07.024","article-title":"Polypoidal choroidal vasculopathy based on non-ICGA criteria in White patients with neovascular age-related macular degeneration","volume":"244","author":"Chaikitmongkol","year":"2022","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"10.1016\/j.apjo.2026.100298_bib4","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1097\/01.APO.0000656992.00746.48","article-title":"Latest developments in polypoidal choroidal vasculopathy: epidemiology, etiology, diagnosis, and treatment","volume":"9","author":"Chaikitmongkol","year":"2020","journal-title":"Asia Pac J Ophthalmol (Philos"},{"key":"10.1016\/j.apjo.2026.100298_bib5","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jamaophthalmol.2017.4030","article-title":"Efficacy and safety of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy","volume":"135","author":"Koh","year":"2017","journal-title":"JAMA Ophthalmol"},{"issue":"9","key":"10.1016\/j.apjo.2026.100298_bib6","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1001\/jamaophthalmol.2020.2443","article-title":"Comparison of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: the EVEREST II randomized clinical trial","volume":"138","author":"Lim","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.apjo.2026.100298_bib7","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1001\/jamaophthalmol.2018.1804","article-title":"Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy in the PLANET study","volume":"136","author":"Lee","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.apjo.2026.100298_bib8","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ajo.2019.02.027","article-title":"PLANET Investigators. Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy: two-year results of the aflibercept in polypoidal choroidal vasculopathy study","volume":"204","author":"Wong","year":"2019","journal-title":"Am J Ophthalmol"},{"issue":"9","key":"10.1016\/j.apjo.2026.100298_bib9","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1016\/j.ophtha.2015.05.024","article-title":"One-year results of intravitreal aflibercept for polypoidal choroidal vasculopathy","volume":"122","author":"Yamamoto","year":"2015","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.apjo.2026.100298_bib10","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1097\/IAE.0000000000000933","article-title":"Aflibercept for polypoidal choroidal vasculopathy: as needed versus fixed interval dosing","volume":"36","author":"Inoue","year":"2016","journal-title":"Retina"},{"issue":"7","key":"10.1016\/j.apjo.2026.100298_bib11","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1136\/bjophthalmol-2020-318354","article-title":"Efficacy of a novel personalised aflibercept monotherapy regimen based on polypoidal lesion closure in participants with polypoidal choroidal vasculopathy","volume":"106","author":"Teo","year":"2022","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"10.1016\/j.apjo.2026.100298_bib12","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.oret.2021.03.012","article-title":"Timing of complete polypoidal regression after intravitreous aflibercept treatments in polypoidal choroidal vasculopathy","volume":"6","author":"Chaikitmongkol","year":"2022","journal-title":"Ophthalmol Retin"},{"issue":"1","key":"10.1016\/j.apjo.2026.100298_bib13","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3341\/kjo.2020.0096","article-title":"One-year results of aflibercept treatment for polypoidal choroidal vasculopathy with good visual acuity","volume":"35","author":"Kwon","year":"2021","journal-title":"Korean J Ophthalmol"},{"issue":"2","key":"10.1016\/j.apjo.2026.100298_bib14","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1089\/jop.2023.0124","article-title":"Impact of prolonged persisting subretinal fluid on the outcome of aflibercept treatment in neovascular age-related macular degeneration","volume":"40","author":"Lee","year":"2024","journal-title":"J Ocul Pharm Ther"},{"issue":"4","key":"10.1016\/j.apjo.2026.100298_bib15","first-page":"379","article-title":"Impact of polyp regression on 2-year outcomes of intravitreal aflibercept injections: a treat-and-extend regimen for polypoidal choroidal vasculopathy","volume":"72","author":"Morizane-Hosokawa","year":"2018","journal-title":"Acta Med Okayama"},{"issue":"8","key":"10.1016\/j.apjo.2026.100298_bib16","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1097\/IAE.0b013e31824f91e8","article-title":"EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy","volume":"32","author":"Koh","year":"2012","journal-title":"Retina"},{"issue":"6","key":"10.1016\/j.apjo.2026.100298_bib17","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1001\/jamaophthalmol.2019.0565","article-title":"Sensitivity and Specificity of Potential Diagnostic Features Detected Using Fundus Photography, Optical Coherence Tomography, and Fluorescein Angiography for Polypoidal Choroidal Vasculopathy","volume":"137","author":"Chaikitmongkol","year":"2019","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.apjo.2026.100298_bib18","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/IAE.0000000000002902","article-title":"Ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: predictors of visual and anatomical response in the EVEREST II study","volume":"41","author":"Cheung","year":"2021","journal-title":"Retina"},{"issue":"11","key":"10.1016\/j.apjo.2026.100298_bib19","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1136\/bjophthalmol-2011-300285","article-title":"Predictive factors of resolved retinal fluid after intravitreal ranibizumab for polypoidal choroidal vasculopathy","volume":"95","author":"Koizumi","year":"2011","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"10.1016\/j.apjo.2026.100298_bib20","article-title":"Recurrence and visual prognostic factors of polypoidal choroidal vasculopathy: 5-year results","volume":"11","author":"Kim","year":"2021","journal-title":"Sci Rep"},{"issue":"11","key":"10.1016\/j.apjo.2026.100298_bib21","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1097\/IAE.0000000000003595","article-title":"Predictors and importance of complete polypoidal lesion regression in the EVEREST II study: predictors of polyp regression in polypoidal choroidal vasculopathy","volume":"42","author":"Tan","year":"2022","journal-title":"Retina"},{"issue":"9","key":"10.1016\/j.apjo.2026.100298_bib22","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1097\/IAE.0b013e31828bcafa","article-title":"Factors predictive of outcomes 1 year after 3 monthly ranibizumab injections and as-needed reinjections for polypoidal choroidal vasculopathy in Japanese patients","volume":"33","author":"Hikichi","year":"2013","journal-title":"Retina"},{"issue":"5","key":"10.1016\/j.apjo.2026.100298_bib23","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1007\/s10384-018-0605-6","article-title":"Prognostic factors after aflibercept therapy for typical age-related macular degeneration and polypoidal choroidal vasculopathy","volume":"62","author":"Ogasawara","year":"2018","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.apjo.2026.100298_bib24","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1007\/s00417-015-3221-x","article-title":"Subfoveal choroidal thickness as a predictor of treatment response to anti-vascular endothelial growth factor therapy for polypoidal choroidal vasculopathy","volume":"254","author":"Kim","year":"2016","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"8","key":"10.1016\/j.apjo.2026.100298_bib25","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1097\/IAE.0000000000001758","article-title":"Choroidal vascular hyperpermeability as a predictor of treatment response for polypoidal choroidal vasculopathy","volume":"38","author":"Yanagi","year":"2018","journal-title":"Retina"},{"issue":"1","key":"10.1016\/j.apjo.2026.100298_bib26","doi-asserted-by":"crossref","DOI":"10.1080\/07853890.2024.2393273","article-title":"Exploring and identifying the imaging biomarkers for predicting anti-VEGF treatment response in polypoidal choroidal vasculopathy: a prospective multicenter study","volume":"56","author":"Zhang","year":"2024","journal-title":"Ann Med"}],"container-title":["Asia-Pacific Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162098926000241?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162098926000241?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T04:07:15Z","timestamp":1775448435000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162098926000241"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2162098926000241"],"URL":"https:\/\/doi.org\/10.1016\/j.apjo.2026.100298","relation":{},"ISSN":["2162-0989"],"issn-type":[{"value":"2162-0989","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Factors predicting fluid-free retina and complete polypoidal regression in polypoidal choroidal vasculopathy eyes receiving 2-mg aflibercept treatments","name":"articletitle","label":"Article Title"},{"value":"Asia-Pacific Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apjo.2026.100298","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc. on behalf of Asia-Pacific Academy of Ophthalmology and Academy of Asia-Pacific Professors of Ophthalmology.","name":"copyright","label":"Copyright"}],"article-number":"100298"}}